Journal article
Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies
The European respiratory journal, Vol.50(2), pp.1700017-1700017
08/2017
DOI: 10.1183/13993003.00017-2017
PMCID: PMC5593347
PMID: 28860266
Abstract
Bronchial thermoplasty is an endoscopic therapy for severe asthma. The previously reported, randomised sham-controlled AIR2 (Asthma Intervention Research 2) trial showed a significant reduction in severe asthma exacerbations, emergency department visits and hospitalisations after bronchial thermoplasty. More "real-world" clinical outcome data is needed.This article compares outcomes in bronchial thermoplasty subjects with 3 years of follow-up from the ongoing, post-market PAS2 (Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma) study with those from the AIR2 trial.279 subjects were treated with bronchial thermoplasty in the PAS2 study. We compared the first 190 PAS2 subjects with the 190 bronchial thermoplasty-treated subjects in the AIR2 trial at 3 years of follow-up. The PAS2 subjects were older (mean age 45.9
40.7 years) and more obese (mean body mass index 32.5
29.3 kg·m
) and took higher doses of inhaled corticosteroids (mean dose 2301
1961 μg·day
). More PAS2 subjects had experienced severe exacerbations (74%
52%) and hospitalisations (15.3%
4.2%) in the 12 months prior to bronchial thermoplasty. At year 3 after bronchial thermoplasty, the percentage of PAS2 subjects with severe exacerbations, emergency department visits and hospitalisations significantly decreased by 45%, 55% and 40%, respectively, echoing the AIR2 results.The PAS2 study demonstrates similar improvements in asthma control after bronchial thermoplasty compared with the AIR2 trial despite enrolling subjects who may have had poorer asthma control.
Details
- Title: Subtitle
- Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies
- Creators
- Geoffrey Chupp - Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA Geoffrey.chupp@yale.eduMichel Laviolette - Institut Universitaire de cardiologie et pneumonologie de Quebec, Université Laval, Quebec, QC, CanadaLauren Cohn - Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT, USACharlene McEvoy - HealthPartners Institute, Regions Hospital, St Paul, MN, USASandeep Bansal - Penn Highlands Healthcare, DuBois, PA, USAAdrian Shifren - Washington University School of Medicine, St Louis, MO, USASumita Khatri - The Cleveland Clinic Foundation, Cleveland, OH, USAG Mark Grubb - Boston Scientific Corporation, Marlborough, MA, USAEdmund McMullen - Boston Scientific Corporation, Marlborough, MA, USARacho Strauven - Boston Scientific Corporation, Marlborough, MA, USAJoel N Kline - University of Iowa Hospitals and Clinics, Iowa City, IA, USAPAS2 Study Group
- Resource Type
- Journal article
- Publication Details
- The European respiratory journal, Vol.50(2), pp.1700017-1700017
- DOI
- 10.1183/13993003.00017-2017
- PMID
- 28860266
- PMCID
- PMC5593347
- ISSN
- 0903-1936
- eISSN
- 1399-3003
- Grant note
- P30 ES005605 / NIEHS NIH HHS UL1 TR001863 / NCATS NIH HHS
- Language
- English
- Date published
- 08/2017
- Academic Unit
- Pulmonary, Critical Care, and Occupational Medicine; Occupational and Environmental Health; Internal Medicine
- Record Identifier
- 9984094667402771
Metrics
15 Record Views